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Abstract 
This report describes the production of ERM®-AD455k/IFCC, which is a material certified for the catalytic activity concentration of creatine kinase (CK). 
This material was produced in collaboration with the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) following ISO 
Guide 34:2009 and it is certified in accordance with ISO Guide 35:2006. 
The starting material was a recombinant form of human CK isoenzyme MM (CK-MM) expressed in E. coli. It was produced, purified, filled and 
lyophilised by Asahi Kasei Pharma Corporation (Tokyo, Japan). 
Between unit-homogeneity was quantified and stability during dispatch and storage were assessed in accordance with ISO Guide 35:2006. 
The material was characterised by an interlaboratory comparison of laboratories of demonstrated competence and adhering to ISO/IEC 17025:2005. 
Uncertainties of the certified values were calculated in accordance with the Guide to the Expression of Uncertainty in Measurement (GUM) and include 
uncertainties related to possible inhomogeneity, instability and characterisation. 
The material is intended for the assessment of method performance of the IFCC primary reference measurement procedure for the measurement of 
the catalytic activity concentration of CK at 37 °C. As with any reference material, it can be used for establishing control charts or validation studies. 
The CRM is available in glass vials containing lyophilised material from 1 mL of CK solution. The minimum amount of sample to be used is 12 µL after 
reconstitution of the whole content in one vial. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by the partners of the European Reference Materials consortium.
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1 
Summary 
This report describes the production of ERM®-AD455k/IFCC, which is a material certified for 
the catalytic activity concentration of creatine kinase (CK). This material was produced in 
collaboration with the International Federation for Clinical Chemistry and Laboratory 
Medicine (IFCC) following ISO Guide 34:2009 [1] and it is certified in accordance with ISO 
Guide 35:2006 [2]. 
The starting material was a recombinant form of human CK isoenzyme MM (CK-MM) 
expressed in E. coli. It was produced, purified, filled and lyophilised by Asahi Kasei Pharma 
Corporation (Tokyo, Japan). 
Between unit-homogeneity was quantified and stability during dispatch and storage were 
assessed in accordance with ISO Guide 35:2006 [2]. 
The material was characterised by an interlaboratory comparison of laboratories of 
demonstrated competence and adhering to ISO/IEC 17025:2005 [3]. 
Uncertainties of the certified values were calculated in accordance with the Guide to the 
Expression of Uncertainty in Measurement (GUM) [4] and include uncertainties related to 
possible inhomogeneity, instability and characterisation. 
The material is intended for the assessment of method performance of the IFCC primary 
reference measurement procedure for the measurement of the catalytic activity concentration 
of CK at 37 °C. As with any reference material, it can be used for establishing control charts 
or validation studies. The CRM is available in glass vials containing lyophilised material from 
1 mL of CK solution. The minimum amount of sample to be used is 12 µL after reconstitution 
of the whole content in one vial. 
The CRM was accepted as European Reference Material (ERM®) after peer evaluation by 
the partners of the European Reference Materials consortium. 
The following value was assigned: 
 
 
 
Certified value2) Uncertainty3) 
Catalytic activity 
concentration 1) 
314 U/L 
5.2 µkat/L 
6 U/L 
0.1 µkat/L 
1)
 Catalytic activity concentration of creatine kinase isoenzyme MM (CK-MM) in the reconstituted material, as obtained by 
the IFCC primary reference measurement procedure for the measurement of catalytic activity concentration of creatine 
kinase at 37 °C. 
2)
 Certified values are values that fulfil the highest standards of accuracy and represent the unweighted mean value of 
the means of accepted sets of data, each set being obtained in a different laboratory. The certified value and its 
uncertainty are traceable to the International System of Units (SI). Values were converted from U/L into µkat/L by 
multiplication with the factor f = 0.01667. 
3)
 The uncertainty is the expanded uncertainty of the certified value with a coverage factor k = 2 corresponding to a 
level of confidence of about 95 % estimated in accordance with ISO/IEC Guide 98-3, Guide to the Expression of 
Uncertainty in Measurement (GUM:1995), ISO, 2008. 
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3 
4 
Glossary 
ANOVA  Analysis of variance 
CK-MM Creatine kinase MM isoenzyme 
CRM Certified reference material 
C-RSE IFCC Committee for Reference Systems of Enzymes 
EC European Commission 
E. coli Escherichia coli 
ERM® Trademark of European Reference Materials 
EU European Union 
GUM Guide to the Expression of Uncertainty in Measurements 
[ISO/IEC Guide 98-3:2008] 
IFCC International Federation of Clinical Chemistry and Laboratory Medicine 
IRMM Institute for Reference Materials and Measurements of the JRC  
ISO International Organization for Standardization  
k Coverage factor 
kat/L Katal per litre 
m Mass 
MSbetween Mean of squares between-unit from an ANOVA 
MSwithin  Mean of squares within-unit from an ANOVA 
n 
p 
Number of replicates per unit 
Number of datasets 
rel Index denoting relative figures (uncertainties etc.) 
s Standard deviation 
sbb
 Between-unit standard deviation; an additional index "rel" is added when 
appropriate 
sbetween Standard deviation between groups as obtained from ANOVA; an 
additional index "rel" is added as appropriate 
SI International System of Units 
srel Relative standard deviation of all results of the stability study 
swithin Standard deviation within groups as obtained from ANOVA; an additional 
index "rel" is added as appropriate 
swb Within-unit standard deviation 
t  Mean of all ti 
ti Time point for each replicate 
tsl Proposed shelf life 
ttt Proposed transport time 
u Standard uncertainty  
5 
U Expanded uncertainty 
U/L Units per litre 
u*bb  Standard uncertainty related to a maximum between-unit inhomogeneity 
that could be hidden by method repeatability/intermediate precision 
select as appropriate; an additional index "rel" is added as appropriate 
ubb Standard uncertainty related to a possible between-unit inhomogeneity;  
an additional index "rel" is added as appropriate 
uchar  Standard uncertainty of the material characterisation; an additional index 
"rel" is added as appropriate 
uCRM Combined standard uncertainty of the certified value; an additional index 
"rel" is added as appropriate 
UCRM  Expanded uncertainty of the certified value; an additional index "rel" is 
added as appropriate 
u∆ Combined standard uncertainty of measurement result and certified 
value 
U∆ Expanded standard uncertainty of measurement result and certified 
value 
ults Standard uncertainty of the long-term stability; an additional index "rel" is 
added as appropriate 
umeas Standard measurement uncertainty 
usts Standard uncertainty of the short-term stability; an additional index "rel" 
is added as appropriate 
v Volume 
x
 
Arithmetic mean 
∆meas Absolute difference between mean measured value and the certified 
value 
MSwithinν
 
Degrees of freedom of MSwithin 
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1 Introduction  
1.1 Background 
Creatine kinase (CK) is an enzyme that is generally associated with adenosine triphosphate 
regeneration in contractile or transport systems. Its predominant physiologic function occurs 
in muscle cells, where it is involved in the storage and utilisation of high-energy creatine 
phosphate. It is widely distributed in tissues, with highest activities found in skeletal muscle, 
heart muscle, and brain tissue. Creatine kinase is a dimeric molecule consisting of two 
elongated polypeptide subunits termed B (brain type) and M (muscle type) with three known 
cytosolic isoenzymes (MM, MB and BB). The cytosolic isoenzymes can also be named on 
the basis of their electrophoretic mobility towards the anode [5] and are thus called: creatine 
kinase-1 (CK-BB), creatine kinase-2 (CK-MB) and creatine kinase-3 (CK-MM). A fourth 
isoenzyme occurs in mitochondria of several tissues and is composed of a third type of 
subunit [6]. Creatine kinase gene expression is tissue specific as well as developmentally 
and hormonally regulated [7]. Measurement of this enzyme in serum is requested to the 
clinical laboratory most frequently for the diagnosis of acute myocardial infarction. 
The catalytic activity of an enzyme is a property that is measured by the rate of a specified 
chemical reaction under certain experimental conditions. The measurement of this property 
is very important in clinical chemistry, but the standardisation of catalytic activity 
measurements is challenging as a number of parameters influence the enzyme activity (e.g. 
temperature, pH, substrate nature and concentration, activators, inhibitors). Therefore, the 
measurement results are heavily dependent on the measurement procedure used to attain 
them. This led to the development of universally recognised measurement procedures for 
enzymes commonly measured in clinical chemistry, such as the IFCC primary reference 
measurement procedure for the measurement of catalytic activity concentrations of enzymes 
at 37 °C [8]. 
The EU directive on in vitro diagnostic medical devices (Directive 98/79/EC) requires 
traceability of the assigned values of calibrants and control materials to reference 
measurement procedures and/or reference materials of higher order. 
In collaboration with the IFCC Committee for Reference Systems of Enzymes (C-RSE), the 
Institute for Reference Materials and Measurements (IRMM) developed a CRM certified for 
the catalytic activity concentration of CK. This material, ERM-AD455k/IFCC, is intended to be 
used as a quality control material for the IFCC primary reference measurement procedure for 
CK at 37 °C [9]. The homogeneity and the stability of ERM-AD455k/IFCC were demonstrated 
and the certified value was assigned using the IFCC reference measurement procedure at 
37 °C in an interlaboratory comparison of expert laboratories. 
1.2 Choice of the material 
A recombinant CK-MM material from Asahi Kasei Pharma Corporation was selected as 
starting material based on the outcome of a commutability study carried out by IRMM. The 
purity was guaranteed by the provider as containing no other enzyme with a relative catalytic 
activity concentration of more than 1.0 % of the total catalytic activity concentration. The 
material was solubilised in a buffer, frozen and lyophilised to improve long-term stability. The 
aim of the production process was to obtain a material that once reconstituted with 1.0 mL of 
distilled/deionised water would have a catalytic activity concentration of about 300 U/L. The 
selection of the material and the catalytic activity concentration was based on a 
recommendation received from the IFCC C-RSE in 2011. 
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1.3 Design of the CRM project 
A commutability study including nine routine measurement procedures was completed to 
select the most appropriate starting material for the production of  
ERM-AD455k/IFCC. 
The material was certified by interlaboratory comparison of data from expert laboratories 
using the IFCC primary reference measurement procedure for the measurement of the 
catalytic activity concentration of CK at 37 °C [9]. The performances of the laboratories were 
assessed using two serum based control materials. 
The homogeneity and stability of the material were assessed using a UniCel® DxC 800 
Synchron Clinical System with CK reagent cartridges (Beckman Coulter, Inc., Clare, IE). This 
test kit showed a low average relative standard deviation during the commutability study. 
Statistical analysis of the data was done using the software SoftCRM (version 2.0.21) [10]. 
2 Participants 
2.1 Project management and evaluation 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
2.2 Processing  
Asahi Kasei Pharma Corporation, Tokyo, JP 
2.3 Homogeneity and stability study 
European Commission, Joint Research Centre, Institute for Reference Materials and 
Measurements (IRMM), Geel, BE  
(accredited to ISO Guide 34 for production of certified reference materials, BELAC No. 268-RM) 
Beckman Coulter, Inc., Clare, IE 
2.4 Characterisation 
The laboratories are listed below in alphabetic order. This order does not necessarily 
correspond to the ranking of the laboratories L01 to L10 described in the Tables of this 
report. 
*Affiliated Hospital of Nantong University, Reference Laboratory, Nantong, CN  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L6260) 
*Beijing Aerospace General Hospital, Reference Laboratory, Beijing, CN  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195 accreditation, CNAS No. L5536) 
Biosystems, S.A., Barcelona, ES 
*INSTAND e.V., Düsseldorf, DE  
(measurements under the scope of ISO/IEC 17025:2005 accreditation, DAkkS No. D-K-15027-01-00) 
LabWest HagaZiekenhuis, Klinisch Chemisch en Hematologisch Laboratorium, Den Haag, 
NL 
Servizio Di Medicina Di Laboratorio Diagnostica e Ricerca, Ospedale San Raffaele, Milano, 
IT 
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*Sichuan Maker Biotechnology Co., Ltd., Reference System Department, Chengdu, CN 
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2003 accreditation, CNAS No. L6172) 
*Stiftung für Pathobiochemie und Molekulare Diagnostik, Referenzinstitut für Bioanalytik, 
Kalibrierlaboratorium II, Medizinische Hochschule Hannover, Institut für Klinische Chemie, 
Hannover, DE  
(measurements under the scope of ISO/IEC 17025:2005 and ISO15195:2004 accreditation, DAkkS No. D-K-
15117-02-00) 
*Universitat Autònoma de Barcelona, Departament de Bioquímica i Biologia Molecular, Unitat 
de Bioquímica de Medicina, Barcelona, ES  
(measurements under the scope of ISO/IEC 17025:2005 and ISO 15195:2004 accreditation, ENAC No. 
195/LC10.141) 
*Università degli Studi di Milano, Laboratorio Analisi Chimico-Cliniche, Centro 
Interdipartimentale di Ricerca sulla Riferibilità Metrologica in Medicina di Laboratorio, Milano, 
IT  
(measurements under the scope of ISO/IEC 17025 and ISO 15195:2004 accreditation, ACCREDIA No. 217/01) 
*Listed in the JCTLM database for reference measurement services 
 
3 Material processing and process control 
3.1 Origin of the starting material and processing 
The starting material was produced and processed by Asahi Kasei Pharma Corporation. It 
was a recombinant form of human CK-MM expressed in E. coli. The enzyme was purified by 
hydrophobic and anion-exchange chromatography and then dissolved in a buffer (pH 7.5) 
containing among others bovine serum albumin and polysaccharides. The liquid preparation 
was filled in glass vials, frozen and lyophilised. The vials were labelled in the same order as 
the filling sequence using the labels provided by IRMM. 
3.2 Process control 
The final starting material was prepared and tested for activity, stability and homogeneity by 
Asahi Kasei Pharma Corporation. This batch was shown to be homogenous and stable for at 
least one year when stored at -20 °C. 
4 Homogeneity 
A key requirement for any reference material aliquotted into units is equivalence between 
those units. In this respect, it is relevant whether the variation between units is significant 
compared to the uncertainty of the certified value, but it is not relevant if this variation 
between units is significant compared to the analytical variation. Consequently, ISO Guide 34 
[1] requires reference material producers to quantify the between-unit variation. This aspect 
is covered in between-unit homogeneity studies. 
The within-unit inhomogeneity does not influence the uncertainty of the certified value when 
the minimum sample intake is respected, but determines the minimum size of an aliquot that 
is representative for the whole unit. 
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4.1 Between-unit homogeneity 
The between-unit homogeneity was evaluated to ensure that the certified value of the CRM 
is valid for all vials of the material, within the stated uncertainty. 
The number of vials selected corresponds to approximately the cube root of the total number 
of vials produced. The 20 vials were selected using a random stratified sampling scheme 
covering the whole batch for the between-unit homogeneity test. For this, the batch was 
divided into 20 groups (with a similar number of vials) and one vial was selected randomly 
from each group. After reconstitution, three samples were taken from each selected vial, and 
analysed with a UniCel® DxC 800 Synchron Clinical System using CK reagent cartridges. 
The measurements were performed under repeatability conditions, and in a randomised 
manner to be able to separate a potential trend in the analytical sequence from a trend in the 
filling sequence. 
Regression analyses were performed to evaluate potential trends in the analytical sequence 
as well as trends in the filling sequence. No trends in the filling sequence or the analytical 
sequence were observed at a 95 % confidence level. 
The dataset was assessed for consistency using Grubbs outlier tests at a confidence level of 
99 % on the individual results and on the unit means. No outlying individual results and 
outlying unit means were detected. All the data were retained for statistical analysis. 
Quantification of between-unit inhomogeneity was undertaken by analysis of variance 
(ANOVA), which separates the between-unit variation (sbb) from the within-unit variation (swb). 
The latter is equivalent to the method repeatability if the individual samples were 
representative for the whole vial. 
Evaluation by ANOVA requires mean values per vial, which follow at least a unimodal 
distribution and results for each vial that follow unimodal distributions with approximately the 
same standard deviations. The distribution of the mean values per vial was visually tested 
using histograms and normal probability plots.  
It should be noted that sbb,rel and swb,rel are estimates of the standard deviations and are 
therefore subject to random fluctuations. Therefore, the mean square between groups 
(MSbetween) can be smaller than the mean squares within groups (MSwithin), resulting in 
negative arguments under the square root used for the estimation of the between-unit 
variation, whereas the true variation cannot be lower than zero. In this case, u*bb, the 
maximum inhomogeneity that could be hidden by method repeatability, was calculated as 
described by Linsinger et al. [11]. u*bb is comparable to the limit of detection of an analytical 
method It describes the maximum inhomogeneity that might be hidden in the frame of the 
given study setup. 
Method repeatability (swb,rel), between-unit standard deviation (sbb,rel) and u*bb,rel were 
calculated as: 
x
,
within
relwb
MS
s =
 Equation 1 
x
n
MSMS
s
withinbetween
relbb
−
=
,
 Equation 2 
x
νn
MS
u MSwithin
within
*
relbb
4
,
2
=
 Equation 3 
MSwithin mean of squares within-unit from an ANOVA  
MSbetween mean of squares between-unit from an ANOVA 
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x  mean of all results of the homogeneity study 
n mean number of replicates per unit 
MSwithinν  degrees of freedom of MSwithin  
 
The results of the evaluation of the between-unit variation are summarised in Table 1. The 
resulting values from the above equations were converted into relative uncertainties. 
Table 1: Results of the homogeneity study 
ERM-AD455k/IFCC swb,rel [%]
 
sbb,rel 
[%]
 
u*bb,rel 
[%] 
Catalytic activity concentration of CK  0.5 0.5 0.1 
 
The homogeneity study showed no outlying unit means or trends in the filling sequence. 
Therefore the between-unit standard deviation can be used as estimate of ubb. As u*bb sets 
the limits of the study to detect inhomogeneity, the larger value of sbb and u*bb is adopted as 
uncertainty contribution to account for potential inhomogeneity. 
4.2 Within-unit homogeneity and minimum sample intake 
The within-unit homogeneity is closely correlated to the minimum sample intake. The 
minimum sample intake is the minimum amount of sample that is representative for the 
whole unit and thus should be used in an analysis. Using sample sizes equal or above the 
minimum sample intake guarantees the certified value within its stated uncertainty.  
Homogeneity and stability experiments were performed using a 12 µL sample intake. This 
sample intake gives acceptable repeatability, demonstrating that the within-unit 
inhomogeneity no longer contributes to analytical variation at this sample intake. 
5 Stability 
Stability testing is necessary to establish the conditions for storage (long-term stability) as 
well as the conditions for dispatch of the materials to the customers (short-term stability).  
Time, temperature, light (including ultraviolet radiation) and water content were regarded as 
the most relevant influences on the stability of the materials. The influence of ultraviolet or 
visible light was minimised by storing the material in the dark and dispatched in boxes, thus 
removing any possibility of degradation by light. The water content was reduced by freeze-
drying to obtain a stable material. Therefore, only the influences of time and temperature 
needed to be investigated. 
During transport, especially in summer time, temperatures up to 60 °C can be reached and 
stability under these conditions must be demonstrated, if the samples are to be transported 
without any additional cooling. 
The stability studies were carried out using an isochronous design [12]. In this approach, 
samples were stored for a particular length of time at different temperature conditions. 
Afterwards, the samples were moved to conditions where further degradation can be 
assumed to be negligible (reference conditions). At the end of the isochronous storage, the 
samples were analysed simultaneously under repeatability conditions which greatly improves 
the sensitivity of the stability tests. 
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5.1 Short-term stability study 
For the short-term stability study, samples were stored at -20 °C, 4 °C and 60 °C for 0, 1, 2 
and 4 weeks (at each temperature). The reference temperature was set to -70 °C. Two vials 
per storage time were selected using a random stratified sampling scheme. After 
reconstitution, three samples were measured from each vial with a UniCel DxC 800 
Synchron Clinical System using CK reagent cartridges. The measurements were performed 
under repeatability conditions, and a randomised sequence was used to differentiate any 
potential analytical drift from a trend over storage time. 
The data were evaluated individually for each temperature. The results were screened for 
outliers using the single and double Grubbs test on a confidence level of 99 %. One outlying 
individual result was found (Table2). As no technical reason for the outlier could be found all 
data were retained for statistical analysis. 
In addition, the data were evaluated against storage time, and regression lines of catalytic 
activity concentration versus time were calculated, to test for potential increases/decrease of 
the measurand due to shipping conditions. The slopes of the regression lines were tested for 
statistical significance.  
The results of the measurements are shown in Annex B. The results of the statistical 
evaluation of the short-term stability are summarised in Table 2. 
Table 2: Results of the short-term stability test 
ERM-AD455k/IFCC 
Number of individual outlying 
results* Significance of the trend** 
-20 ºC 4 °C 60 ºC -20 ºC 4 °C 60 ºC 
Catalytic activity 
concentration of CK  none
 
1-statistical 
reason 
(retained) 
none no no yes 
*  99 % confidence level 
** 95 % confidence level 
Only one statistical outlier was detected on a 99 % confidence level and retained for the 
estimation of uSTS. The only trend statistically significant on a 95 % confidence level was 
found for storage at 60 °C. 
Although the material is stable at 4 °C for 4 weeks, it shall be shipped on dry ice to avoid the 
introduction of a temperature shift (influence on catalytic activity concentration not evaluated) 
since the long-term storage temperature is -20 °C. 
5.2 Long-term stability study 
For the long-term stability study, samples were stored at -20 °C and 4 °C for 0, 4, 8 and 12 
months (at each temperature). The reference temperature was set to -70 °C. Two samples 
per storage time were selected using a random stratified sampling scheme. After 
reconstitution, three samples were measured from each vial with a UniCel DxC 800 
Synchron Clinical System using CK reagent cartridges. The measurements were performed 
under repeatability conditions, in a random sequence to be able to separate any potential 
analytical drift from a trend over storage time. 
The long-term stability data were evaluated individually for each temperature. The results 
were screened for outliers using the single and double Grubbs test at a confidence level of 
99 %. No outlying individual results were found and all data were retained for statistical 
analysis. 
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In addition, the data were plotted against storage time and linear regression lines of catalytic 
activity concentration versus time were calculated. The slopes of the regression lines were 
tested for statistical significance (loss/increase due to storage). A significant trend was 
detected at a 95 % confidence level for storage at 4 °C. 
The results of the long-term stability measurements are shown in Annex C. 
The material shall be stored at -20 °C. 
5.3 Estimation of uncertainties 
Since there are always variations on measurement results, no study can entirely rule out 
degradation of materials, even in the absence of statistically significant trends. It is therefore 
necessary to quantify the potential degradation. This degradation could be hidden in the 
frame of the study set up, i.e. to estimate the uncertainty of stability. This means that, even 
under ideal conditions, the outcome of a stability study can only be that there is no detectable 
degradation within an uncertainty to be estimated. 
The uncertainties of stability during dispatch and storage were estimated, as described in 
[13]. In this approach, the uncertainty of the linear regression line with a slope of zero was 
calculated. The uncertainty contributions usts and ults were calculated as the product of the 
chosen transport time/shelf life and the uncertainty of the regression lines as: 
( ) tti
rel
relsts
t
t
t
su
⋅
−
=
∑
2,
 Equation 4 
( ) sli
rel
rellts
t
t
t
su
⋅
−
=
∑
2,
 Equation 5 
srel  relative standard deviation of all results of the stability study 
ti time elapsed at time point i 
t  mean of all ti 
ttt chosen transport time (1 week at -20 ºC) 
tsl chosen shelf life (12 months at -20 ºC) 
The following uncertainties were estimated: 
- usts,rel, the uncertainty of degradation during dispatch. This was estimated from the 
short-term stability studies at -20 °C. The uncertainty describes the possible change 
during a dispatch at -20 °C lasting for one week. 
- ults,rel, the stability during storage. This uncertainty contribution was estimated from 
the long-term stability studies at -20 °C. The uncertainty contribution describes the 
possible degradation during 12 months storage at -20 °C. 
The results of these evaluations are summarised in Table 3. 
Table 3: Uncertainties of stability during dispatch and storage. usts,rel was calculated for 
a temperature of -20 °C and 1 week; ults,rel was calculated for a storage temperature of  
-20 °C and 12 months 
ERM-AD455k/IFCC usts,rel [%] 
ults,rel 
[%] 
Catalytic activity concentration of CK  0.1 0.5 
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The material showed significant degradation at 60 °C, but no significant degradation was 
observed for transport below 4 °C. Transport on dry ice is therefore necessary. 
After the certification study, the material will be included in the IRMM's regular stability 
monitoring programme, to control its further stability. 
6 Characterisation 
The material characterisation is the process of determining the property value of a reference 
material. 
This was based on an interlaboratory comparison of data from expert laboratories, i.e. the 
catalytic activity concentration of CK in the material was determined in different laboratories. 
All participants used the IFCC primary reference measurement procedures for the 
measurement of catalytic activity concentration of CK at 37 °C [9] for the measurements. 
Using an interlaboratory comparison aims at randomisation of laboratory bias, which reduces 
the combined uncertainty. 
6.1 Selection of participants 
Ten laboratories were selected based on criteria that comprised both technical competence 
and quality management aspects. Each participant was required to operate a quality system 
and to deliver documented evidence of its laboratory proficiency in the field of catalytic 
activity concentration measurements of enzymes using the IFCC primary reference 
measurement procedure for the measurement of catalytic activity concentrations at 37 °C. 
Having a formal accreditation was not mandatory, but meeting the requirements of ISO/IEC 
17025 was obligatory. Where measurements are covered by the scope of accreditation, the 
accreditation number is stated in the list of participants (Section 2). 
6.2 Study setup 
Each laboratory received six vials of ERM-AD455k/IFCC and was requested to provide six 
independent results, one per vial. The vials for material characterisation were selected using 
a random stratified sampling scheme and covered the whole batch. The sample preparations 
and measurements had to be spread over at least two days to ensure intermediate precision 
conditions. Each participant was also required to analyse two blinded quality control 
samples. 
Laboratories were also requested to give estimations of the expanded uncertainties of the 
mean value of the six results. All GUM approaches were regarded as equally valid 
procedures. 
6.3 Method used 
All laboratories used the IFCC primary reference measurement procedure for the 
measurement of the catalytic activity concentration of CK at 37 °C [9,14]. 
6.4 Evaluation of results 
The characterisation study resulted in eight accepted datasets. All accepted individual results 
of the participants are displayed in tabular and graphical form in Annex D. 
6.4.1 Technical evaluation 
The following criteria were considered during the evaluation: 
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- compliance with the analysis protocol: sample preparations and measurements 
performed on two days 
- performance in measuring the quality control samples 
Based on the above criteria, the dataset from one laboratory (L05) was not included in the 
evaluation based on their performance in measuring the quality control samples. 
6.4.2 Statistical evaluation 
The datasets accepted based on technical reasons were tested for normality of dataset 
means using kurtosis/skewness tests and normal probability plots and were tested for 
outlying means using the Grubbs test and using the Cochran test for outlying standard 
deviations, (both at a 99 % confidence level). Standard deviations within (swithin) and between 
(sbetween) laboratories were calculated using one-way ANOVA. The results of these 
evaluations are shown in Table 4. 
Table 4: Statistical evaluation of the technically accepted datasets for ERM-
AD455k/IFCC. p: number of technically valid datasets 
ERM-
AD455k/IFCC p 
Outliers Normally 
distributed 
Statistical parameters 
Means Variances Mean [U/L] 
s 
[U/L] 
sbetween 
[U/L] 
swithin 
[U/L] 
Catalytic activity 
concentration of 
CK  
9 none none yes 313.48 6.32 5.87 2.48 
 
The laboratory means follow normal distributions. None of the data contains outlying means 
and variances. The datasets are therefore consistent and the mean of laboratory means is a 
good estimate of the true value. Standard deviations between laboratories are considerably 
larger than the standard deviation within laboratories, showing that confidence intervals of 
replicate measurements are unsuitable as estimate of measurement uncertainty. 
The uncertainty related to the characterisation is estimated as the standard error of the mean 
of laboratory means (Table 5). 
Table 5: Uncertainty of characterisation for ERM-AD455k/IFCC 
ERM-AD455k/IFCC p Mean [U/L] 
s 
[U/L] 
uchar,rel 
[%] 
Catalytic activity concentration of CK  9 314 6 0.6 
 
7 Value Assignment 
Based on the results of the characterisation study a certified value for the catalytic activity 
concentration of CK was assigned to ERM-AD455k/IFCC. 
Certified values are values that fulfil the highest standards of accuracy. Procedures at IRMM 
require generally pooling of not less than six datasets to assign certified values. Full 
uncertainty budgets in accordance with the 'Guide to the Expression of Uncertainty in 
Measurement' [4] were established. 
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7.1 Certified values and their uncertainties 
The unweighted mean of the means of the accepted datasets as shown in Table was 
assigned as certified value. 
The assigned uncertainty consists of uncertainties relating to characterisation, uchar (Section 
6), potential between-unit inhomogeneity, ubb (Section 4.1), and potential degradation during 
transport, usts, and long-term storage, ults (Section 5). These different contributions were 
combined to estimate the relative expanded uncertainty of the certified value (UCRM, rel) with a 
coverage factor k given as:  
2
rel char,
2
rel lts,
2
rel sts,
2
rel bb,rel CRM, uuuukU +++⋅=  Equation 6 
- uchar was estimated as described in Section 6 
- ubb was estimated as described in Section 4.1 
- usts and ults were estimated as described in section 5.3 
A coverage factor k of 2 was applied, to obtain the expanded uncertainty. The certified value 
and its uncertainties are summarised in Table 6. 
Table 6: Certified value and its uncertainties for ERM-AD455k/IFCC 
ERM-DA455k/IFCC Certified value [U/L] 
uchar,rel 
[%] 
ubb,rel 
[%]
 
usts,rel 
[%] 
ults,rel 
[%] 
UCRM1) 
[U/L] 
Catalytic activity 
concentration of CK  314 0.6 0.5 0.1 0.5 6 
1)
 Expanded (k = 2) and rounded uncertainty. 
The International Union of Pure and Applied Chemistry and the International Union of 
Biochemistry recommended that enzyme concentration is expressed in terms of katals per 
liter (kat/L) [14]. This name and symbol were approved by the General Conference on 
Weights and Measures and is consistent with the International System of Units (SI) as  
kat = mol/s. However, different units have been introduced in the past. Therefore, the 
Commission on Enzymes of the International Union of Biochemistry proposed the term 
international unit (U) as the quantity of enzyme that catalyses the reaction of 1 µmol of 
substrate per minute. Catalytic activity concentration is then to be expressed in terms of U/L 
[15, 16]. Enzyme units (U) are still more commonly used than the katal, especially in 
biochemistry. Therefore, the certified value for ERM-AD455k/IFCC is expressed both in 
µkat/L and in U/L in this certification report as well as on the certificate. The catalytic activity 
concentration in µkat/L can easily be converted to U/L by multiplying with the factor f = 60. 
1 µkat/L = 60 U/L 
1 U = 10-6 mol/60 s = 16.7 x 10-9 mol/s 
8 Metrological traceability and commutability 
8.1 Metrological traceability  
Identity 
The catalytic activity concentration of CK is a method-defined measurand and can only be 
obtained by following the procedure specified in the IFCC primary reference measurement 
procedure at 37 °C [9]. Adherence to this procedure was confirmed by agreement of the 
laboratories' results with the assigned value for the samples that were used as quality control 
samples and by comparison among laboratory results. The measurand is therefore 
operationally defined by method. 
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Quantity value 
Traceability of the obtained results is based on the traceability of all relevant input factors. 
Instruments in individual laboratories were verified and calibrated with measurement 
standards ensuring traceability to the SI. Consistency in the interlaboratory comparison 
demonstrates that all relevant input factors were covered. As the assigned value is a 
combination of agreeing results individually traceable to the SI, the assigned quantity value 
itself is traceable to the SI. 
8.2 Commutability 
Many measurement procedures include one or more steps which select specific (or specific 
groups of) analytes from the sample for the subsequent whole measurement process. Often 
the complete identity of these 'intermediate analytes' is not fully known or taken into account. 
Therefore, it is difficult to mimic all analytically relevant properties of real samples within a 
CRM. The degree of equivalence in the analytical behaviour of real samples and a CRM with 
respect to various measurement procedures (methods) is summarised in a concept called 
'commutability of a reference material'. There are various definitions that define this concept. 
For instance, the Clinical and Laboratory Standards Institute Guideline C53-A [17] 
recommends the use of the following definition for the term commutability: 
"The equivalence of the mathematical relationships among the results of different 
measurement procedures for an RM and for representative samples of the type intended 
to be measured." 
The commutability of a CRM defines its fitness for use and is therefore a crucial 
characteristic when applying different measurement methods. When the commutability of a 
CRM is not established, the results from routinely used measurement procedures cannot be 
legitimately compared with the certified value to determine whether a bias does not exist in 
calibration, nor can the CRM be used as a calibrant. For instance, CRMs intended to be used 
to establish or verify metrological traceability of routine clinical measurement procedures 
must be commutable for the routine clinical measurement procedures for which they are 
intended to be used. 
A commutability study was carried out on a trial batch of the starting material for ERM-
AD455k/IFCC in collaboration with the IFCC C-RSE. The results were convincing enough to 
process the final batch of the material and to certify its CK catalytic activity concentration. 
However, if ERM-AD455k/IFCC would be used to calibrate routine procedures, extended 
commutability studies should be performed with these procedures. 
9 Instructions for use 
9.1 Safety information 
The usual laboratory safety measures apply. 
The material is for in vitro use only. 
9.2 Storage conditions 
Unopened vials of the material should be stored at (-20 ± 5) °C in the dark. After 
reconstitution, the material must be kept cold (2-8 °C) and must be used within four hours. 
Please note that the European Commission cannot be held responsible for changes that 
happen during storage of the material at the customer's premises, especially for opened 
vials. 
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9.3 Reconstitution 
To prepare ERM-AD455k/IFCC for use, the lyophilised material shall be reconstituted 
according to the following procedure: 
1) Remove vial from freezer and let equilibrate to room temperatures (20-25 °C). 
2) Tap the vertically positioned vial gently to ensure that the lyophilised material is at the 
bottom of the vial. 
3) Carefully open vial, avoiding the loss of lyophilised material. 
4) Weigh the vial with its content to the nearest 0.1 mg. 
5) Reconstitute with (1.00 ± 0.01) mL distilled water (20-22 °C) slowly added to the sides 
of the vial. 
6) Weigh the vial after adding the water and record the weight. 
7) Carefully close the vial. 
8) Allow to stand at room temperature for ten minutes. 
9) Slowly stir up the vial to dissolve the lyophilised material completely. 
10) Calculate the volume of water at 20 °C from the mass of water added taking into 
account the temperature dependent density. 
11) Keep the vial cold (2-8 °C) until use. 
12) The catalytic activity concentration of CK must be measured within four hours following 
the reconstitution*. 
*The activity is not guaranteed after four hours after reconstitution. 
 
9.4 Minimum sample intake 
The minimum sample intake representative for the catalytic activity concentration of CK in 
ERM-AD455k/IFCC is 12 µL as this was the sample intake for the homogeneity study. 
9.5 Use of the certified value 
The main purpose of the material is to control the performance of the IFCC primary reference 
procedure for the measurement of catalytic activity concentration of CK at 37 °C [9]. As any 
reference material, it can be used for establishing control charts or validation studies. 
Use as a calibrant 
It is not recommended to use this material as calibrant. If used nevertheless, the uncertainty 
of the certified value shall be taken into account in the estimation of the measurement 
uncertainty. When the material is used as a calibrant in a routine measurement procedure 
the commutability should be verified for the assay concerned. 
Comparing an analytical result with the certified value 
A result is unbiased if the combined standard uncertainty of measurement and certified value 
covers the difference between the certified value and the measurement result (see also ERM 
Application Note 1, www.erm-crm.org [18]. 
When assessing the method performance, the measured values of the CRMs are compared 
with the certified values. The procedure is summarised here:  
- Calculate the absolute difference between mean measured value and the certified 
value (∆meas). 
- Combine the measurement uncertainty (umeas) with the uncertainty of the  
certified value (uCRM): 22 CRMmeas uuu +=∆  
- Calculate the expanded uncertainty (U∆) from the combined uncertainty (u∆,) using an 
appropriate coverage factor, corresponding to a level of confidence of approximately 
95 %. 
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- If ∆meas ≤ U∆ then no significant difference exists between the measurement result 
and the certified value, at a confidence level of approximately 95 %. 
Use in quality control charts 
The material can be used for quality control charts. Using CRMs for quality control charts has 
the added value that a trueness assessment is built into the chart. 
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Annexes 
Annex A: Results of the homogeneity measurements 
 
Figure A1: Homogeneity data of CK in ERM-AD455k/IFCC as measured with a UniCel DxC 
800 Synchron Clinical System with CK reagent cartridges. Shown are the averages per vial 
number and their 95 % confidence interval based on the standard deviation as derived from 
a one-way ANOVA of all data. 
300
310
320
330
340
350
360
370
380
390
400
0 500 1000 1500 2000 2500 3000
Ca
ta
ly
tic
 
Ac
tiv
ity
 
Co
n
ce
n
tr
at
io
n
 
o
f C
K
 
[U
/L
]
Vial Number
24 
Annex B: Results of the short-term stability measurements 
 
Figure B1: Short-term stability data of CK in ERM-AD455k/IFCC (stored at -20 °C) as 
measured with a UniCel DxC 800 Synchron Clinical System with CK reagent cartridges. 
Shown are the averages per time point and their 95 % confidence interval based on the 
standard deviation as derived from a one-way ANOVA of all data. 
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Annex C: Results of the long-term stability measurements 
 
Figure C1: Long-term stability data of CK in ERM-AD455k/IFCC (stored at -20 °C) as 
measured with a UniCel DxC 800 Synchron Clinical System with CK reagent cartridges. 
Shown are the averages per time point and their 95 % confidence interval based on the 
standard deviation as derived from a one-way ANOVA of all data. 
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Annex D: Results of the characterisation measurements 
Figure D1: Graph showing average enzymatic activity concentrations of CK in  
ERM-AD455k/IFCC as measured with the IFCC primary reference measurement procedure 
at 37 °C with expanded uncertainties as stated by the laboratories and the 95 % certified 
interval (dotted lines). 
 
Table D1: All accepted individual results, the mean value and the expanded uncertainty as 
stated by the laboratories for the catalytic activity concentration measurements of CK in 
ERM-AD455k/IFCC. 
Laboratory  
code 
Replicate 
1 
[U/L] 
Replicate 
2 
[U/L] 
Replicate 
3 
[U/L] 
Replicate 
4 
[U/L] 
Replicate 
5 
[U/L] 
Replicate 
6 
[U/L] 
Mean 
[U/L] 
Expanded  
uncertainty 
[U/L] 
L1 309.2 313.6 311.1 311.1 312.8 308.0 311.0 8.0 
L2 322.74 321.77 324.40 321.41 324.86 321.63 322.8 8.8 
L3 300 310 302 299 302 308 304 6.7 
L4 318.3 313.8 317.2 316.6 315.2 313.4 315.8 9.47 
L6 309.5 312.9 309.8 315.8 317.2 313.3 313.1 7.8 
L7 317.76 313.60 313.72 316.01 313.93 313.97 314.83 6.7 
L8 316.49 319.47 317.33 317.67 320.56 320.69 318.70 7.75 
L9 307.1 306.3 304.5 307.4 306.9 305.4 306.3 2.237 
L10 316 311 314 319 315 318 316 7.9 
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